Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer

Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer

Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1) expression. However, it is not always possible to...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Thoracic Cancer
Subjects:
non‐small cell lung cancer
plasma fibrinogen
programmed cell death ligand 1
SUVmax
Online Access:https://doi.org/10.1111/1759-7714.15453
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.15453

Similar Items